
Chewy Inc. reported stronger-than-expected Q3 results, with CEO Sumeet Singh highlighting an 18% rise in discretionary spending and continued market share gains, driven by growth in veterinary services and membership programs.

Celltrion has internalized hyaluronidase-based SC formulation technology, enabling rapid drug administration and expanding its pipeline, with plans to seek regulatory approval for Herzuma SC and pursue CMO opportunities globally.